Annexin V and anti-Annexin V antibodies: Two interesting aspects in acute myocardial infarction

Thrombosis Journal

Volumn 7, Issue , 2009, Pages

  Shojaie, Mohammad ^a   Sotoodah, Abdoreza ^a   Roozmeh, Shohre ^a   Kholoosi, Ensieh ^a   Dana, Samira ^a  

^a JAHROM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN V ANTIBODY; ANTIBODY; CARDIOLIPIN ANTIBODY; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ANTIBODY DETECTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING;

EID: 68949202989     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-7-13     Document Type: Article

References (39)

1. Zimmerman FH Cameron A Fisher LD NG G Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry) J Am Coll Cardiol 1995, 26:654-61. 10.1016/0735-1097(95)00254-2 7642855
2. Thompson SG Kienast J Pyke SDM Haverkate F Loo Van de JCW Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris N Engl J Med 1995, 332:635-41. 10.1056/ NEJM199503093321003 7845427
3. Jansson JH Nilsson TK Jonson O Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction Heart 1998, 80:334-7. 1728802 9875107
4. Fernández P Marco P Marín F Roldán V Sogorb F The role of tissue plasminogen activator on the progression of the coronary disease Eur Heart J 2002, 23:88. 10.1053/euhj.2001.2633 11741367
5. Rand JH Wu X Andree HAM Ross JBA Rusinova E Gascon-Lema MG Calandri C Harpel P Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A 〈lupus procoagulant〉 phenomenon Blood 1998, 5:1652-60.
6. Reutelingsperger CPM Annexins: Key regulators of haemostasis, thrombosis and apoptosis Thromb Haemost 2001, 86:413-9. 11487032
7. Van Heerde WL De Groot PG Reutelingsperger CPM The complexity of the phospholipid binding protein ANV Thromb Haemost 1995, 73:172-9. 7792726
8. Rand JH Annexinopathies a new class of diseases N Engl J Med 1999, 340:1035-6. 10.1056/NEJM199904013401310 10099148
9. Van Ryn McKenna J Merk H Muller TH Buchanan MR Eisert WG The effect of heparin and annexin V on fibrin accretion after injury in the jugular vein of rabbits Thromb Haemost 1993, 69:227-230. 8470045
10. Van Heerde WL Sakariassen KS Hemker HC Sixma JJ Reutelingsperger CPM DeGroot PG ANV inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under flow conditions Arterioscler Thromb 1994, 14:824-830. 8172859
11. Gerke V Moss SE Annexins: From Structure to Function Physiol Rev 2002, 82:331-371. 11917092
12. Kaburaki J Kuwana M Yamamoto M Kawai S Ikeda Y Clinical significance of anti-ANV antibodies in patients with systemic lupus erythematosus Am J Hematol 1997, 54:209-13. 10.1002/ (SICI)1096-8652(199703)54:3<209::AID-AJH6>3.0.CO;2-# 9067499
13. Ogawa H Zhao D Dlott JS Cameron GS Yamazaki M Hata T Triplett DA Elevated anti-ANV antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities Am J Clin Pathol 2000, 114:619-28. 10.1309/298H-NLBU-E47G-8PYL 11026109
14. Reutelingsperger CP van Heerde WL ANV, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis Cell Mol Life Sci 1997, 53:527-32. 10.1007/s000180050067 9230931
15. Rodriguez-Garcia MI Fernandez JA Rodriguez A Fernandez MP Gutierrez C Torre-Alonso JC ANV auto antibodies in rheumatoid arthritis Ann Rheum Dis 1996, 55(12):895-900. 1010341 9014583 10.1136/ard.55.12.895
16. Lakos G Kiss E Regeczy N Tarjan P Soltesz P Zeher M Bodolay E Szucs G Szakony S Sipka S Szegedi G Antiprothrombin and Antiannexin V Antibodies Imply Risk of Thrombosis in Patients with Systemic Autoimmune Diseases J Rheumatol 2000, 27:924-9. 10782817
17. Gaspersic N Rot U Cucnik S Kveder T Bozic B Rozman B Anti-annexin V antibodies in patients with cerebrovascular disease Ann Rheum Dis 2003, 62:188-189. 1754427 12525397 10.1136/ard.62.2.188
18. Nakamura N Shidara Y Kawaguchi N Azuma C Mitsuda N Onishi S Yamaji K Wada Y Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: Involvement of ANV Biochem Biophys Res Commun 1994, 205:1488-93. 10.1006/bbrc.1994.2833 7802685
19. Rand HJ Wu XX Lapinski R Van Heerde WL Reutelingsperger CP Chen PP Ortel TL Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome Blood 2004, 104:2783-90. 10.1182/blood-2004-01-0203 15242878
20. Cederholm A Svenungsson E Jensen-Urstad K Trollmo C Ulfgren A Swedenborg J Fei GZ Frostegard J Decreased Binding of Annexin V to Endothelial Cells Arterioscler Thromb 2005, 25:198.
21. Roldan V Marín F Pineda J Marco P Corral J Climent V Garcia A Martinez JG sogorb F Anexina VLevals in Survivors of Early Myocardial Infarction Rev Esp Cardiol 2002, 55:1230-4. 12459071
22. Kaneko N Matsuda R Hosoda S Kajita T Ohta Y Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction Clin Chim Acta 1996, 251:65-80. 10.1016/0009-8981(96)06294-8 8814351
23. Antman EM Braunwald E ST-elevation Myocardial Infarction: Pathology, pthophysiology and clinical feature Braunwalds HEART DISEASE Elsevier Saunders company Libby P, Bonow RO, Mann DL, Zipes DP, et al 8 2008, 1224.
24. Cannon CP Braunwald E Un Stable Angina and Non ST-elevation Myocardial Infarction Braunwalds HEART DISEASE Elsevier Saunders company Libby P, Bonow RO, Mann DL, Zipes DP, et al 8 2008, 1322.
25. Victor RG Kaplan NM Systemic Hypertension: Mechanisms and Diagnosis Braunwalds HEART DISEASE Elsevier Saunders company Libby P, Bonow RO, Mann DL, Zipes DP, et al 8 2008, 1027.
26. Foster DW Diabetes Mellitus Harrison's principle of internal medicine Mc Grow Hill company. Philadelphia: USA Fauci AS, Braunwald E, Wilson JD, et al 16 2005, 1822-1838.
27. Lang RM Bierig M Devereux RB Flachskampf FA Foster E Pellikka PA Picard MH Roman MJ Seward J Shanewise JS Solomon SD Spencer KT Sutton MS Stewart WJ Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 2005, 18:1440. 10.1016/j.echo.2005.10.005 16376782
28. Olea JO Annexin V Levels in Young Patients with Acute Myocardial Infarction: New Answers Bring New Questions Rev Esp Cardiol 2002, 55:1223-1225. 12459069
29. Thiagarajan P Benedict CR Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model Circulation 1997, 96:2339-47. 9337209
30. Matsuda R Kaneko N Kikuchi M Chiwaki F Toda M Ieir T Horikawa Y Shimizu M Shimamoto K Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room Resuscitation 2003, 57:171-177. 10.1016/S0300-9572(03)00034-0 12745185
31. Stratton J Dewhurst TA Kasina S Reno JM Cerquira MD Baskin DG Tait JF Selective uptake of radiolabeled ANV on acute porcine left atrial thrombi Circulation 1995, 92:3113-3121. 7586283
32. Rand JH Wu X Antibody-mediated disruption of the annexin-V antithrombotic shield: A new mechanism for thrombosis in the antiphospholipid syndrome Thromb Haemost 1999, 82:649-55. 10605763
33. Hughes GRV The antiphospholipid syndrome: Ten years on Lancet 1993, 342:341-4. 10.1016/0140-6736(93)91477-4 8101587
34. Rand JH Wu XX Andree HA Lockwood CJ Guller S Scher J Harpel PC Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism N Engl J Med 1997, 337:154-60. 10.1056/NEJM199707173370303 9219701
35. Espositoa G Tambya MC Chanseauda Y Servettaza A Guillevinb LR Mouthon L Anti-annexin V antibodies: Are they prothrombotic? Autoimmunity Reviews 2005, 4:55-60. 10.1016/j.autrev.2004.07.006
36. Parslow TGM Immune response Medical Immunology Mc Graw-Hill company, USA Parslow TG, Stites DP, Terr AI, Imboden JB 10 2001:68.
37. Sugiura K Muro Y Anti-annexin V antibodies and digital ischemia in patients with scleroderma J Rheumatol 1999, 26:2168-72. 10529134
38. Kaburaki J Kuwana M Yamamoto M Kawai S Ikeda Y Clinical significance of anti-ANV antibodies in patients with systemic lupus erythematosus Am J Hematol 1997, 54:209-13. 10.1002/ (SICI)1096-8652(199703)54:3<209::AID-AJH6>3.0.CO;2-# 9067499
39. Gaspersic N Ambrozic A Bozic B Majhenc J Svetina S Rozman B Annexin A5 binding to giant phospholipid vesicles is differentially affected by anti-[beta]2-glycoprotein I and anti-annexin A5 antibodies Rheumatol 2007, 46:81-86. 10.1093/rheumatology/kel200